Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAPIRUS: hydroxychloroquine versus placebo for prevention of thrombotic recurrence in primary antiphospholipid syndrome
2017-004416-19Phase 3Terminated
- Sponsor
- Centre Hospitalier Universitaire d'Angers
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in antiphospholipid syndrome (APS) comparing Hydroxychloroquine + vitamin K antagonist with Placebo + vitamin K antagonist (2 arms). Started Dec 2017; status: terminated.
02
Drugs
hydroxychloroquine
03
Conditions
antiphospholipid syndrome (APS)
Beyond the preview
Go deeper on 2017-004416-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004416-19.